
Overview
Pharmbiopol provides contract manufacturing services for dietary supplements, working with production partners. Its services include recipe development, support with registration and documentation, production and packaging, with private-label and white-label options.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 3 of 6 financial statements were filed late (the longest delay 186 days for 2021).
- 2025not filed
- 202428/05/2025
- 202311/09/2024
- 202230/11/2023
- 202117/01/2023
- 202014/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Offer
- Dietary supplement manufacturing
- Recipe development
- Raw materials selection
- Dietary supplement registration
- Tablet production
- Capsule production
- Syrup manufacturing
- Supplement packaging
Websites
The site is available in: Polish and English.
- pharmbiopol.comProdukcja kontraktowa suplementów diety - PharmbiopolWordPress 3.7ElementorGoogle AnalyticsGoogle Tag ManagerYoast SEOWWPMLLLiteSpeed
Trademarks
The company holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2025.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| Famflow | Z.585210 | 3, 5 | Protected | May 27, 2035 | |
| Baby Bloom | Z.580116 | 3, 5 | Protected | Feb 6, 2035 |
| Mark | Protected until | |
|---|---|---|
| Famflow | May 27, 2035 | |
| Baby Bloom | Feb 6, 2035 |
Authorized Representatives
Manner of representation
In the case of a one-person management board, declarations on behalf of the company are made by the member of the management board. In the case of a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Juliusz Janusz Chorąży age 23 | 10 | $135.06 | 10% |
Krzysztof Chorąży age 53 | 90 | $1,215.56 | 90% |
Krzysztof Chorąży and Juliusz Janusz Chorąży hold a combined 100% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2016-04-19.
03 1240 4751 1111 0011 4835 3957
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Symbio-Lab sp. z o.o. | $920,360.37 | symbio-lab.com | ||
| Ossea sp. z o.o. | $165,200.78 | ossea.pl | ||
| Pexon Poland sp. z o.o. | $122,615.96 | pexon.pl | ||
| Fotam Group sp. z o.o. | $122,168.40 | fotamgroup.pl | ||
| Revital Nutrition sp. z o.o. | $119,917.95 | revitalnutrition.pl | ||
| Nutridea sp. z o.o. | $110,940.30 | nutridea.pl | ||
| Fuelup Factory sp. z o.o. | $107,897.20 | fuelupfactory.com | ||
| BIO Balance Dystrybucja sp. z o.o. | $80,536.48 | biobalance.com.pl | ||
| RABO sp. z o.o. | $66,627.52 | rabo-farma.pl | ||
| NEST Pharm sp. z o.o. | $29,891.47 | nestpharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2024-10-17 | Address change (Ul. Władysława Bełzy 10, 35-602, Rzeszów → Ul. Ignacego Łukasiewicza 3, 35-604, Rzeszów) | |
| 2024-10-04 | Name change (Freakers → Pharmbiopol) | |
| 2024-10-04 | PKD change (Removed: 1 code; Added: 9 codes) | |
| 2016-04-05 | Entered in the register |
FAQ
Last updated: 2026-04-17